# Orforglipron + SLU-PP-332 (Capsule)

> Markdown version of this page, for agents. To send a shopper here, link https://www.besthealthiq.com/__fluid_affiliate_username__/posts/orforglipron-plus-slu-pp-332-capsule (not this .md URL, and keep its path as given).

- Published: 2026-08-29
- Author: Best Health IQ
- Summary: An oral GLP-1 receptor agonist combined with an ERRα/γ agonist for comprehensive metabolic optimization.
- Shopper link: https://www.besthealthiq.com/__fluid_affiliate_username__/posts/orforglipron-plus-slu-pp-332-capsule

### Orforglipron + SLU-PP-332 Capsule An oral GLP-1 receptor agonist combined with an ERRα/γ agonist for comprehensive metabolic optimization. \*\*Category:\*\* Metabolic & Weight · \*\*Evidence:\*\* Moderate Evidence · \*\*Status:\*\* Research Only ### Description This combination pairs Orforglipron (an oral non-peptide GLP-1 receptor agonist currently in Phase III clinical trials by Eli Lilly) with SLU-PP-332 (an ERRalpha/gamma agonist that mimics the molecular effects of endurance exercise). Orforglipron represents a major advance in metabolic medicine as the first oral non-peptide GLP-1 receptor agonist, potentially offering the weight loss benefits of injectable semaglutide (Ozempic/Wegovy) in a convenient daily pill. Phase II data showed significant weight loss and glycemic improvements comparable to injectable GLP-1 agonists. SLU-PP-332 was identified in 2023 research as a potent activator of estrogen-related receptors that drives mitochondrial biogenesis and fat oxidation, mimicking the metabolic adaptations of endurance exercise training. Together, these two compounds address weight loss from complementary angles: Orforglipron reduces appetite and caloric intake through central GLP-1 signaling, while SLU-PP-332 increases the metabolic rate and fat oxidation capacity of peripheral tissues. ### Key Characteristics - \*\*Half-Life:\*\* Varies - \*\*Administration Routes:\*\* Oral capsule - \*\*Typical Dose:\*\* One capsule (per prescriber guidance) - \*\*Frequency:\*\* Daily ### Investigated Benefits - Appetite suppression (Orforglipron) - Improved glycemic control - Mitochondrial biogenesis (SLU-PP-332) - Weight loss - Convenient oral administration \_Benefits based on preclinical/animal research unless otherwise noted.\_ ### Mechanism of Action “An oral GLP-1 receptor agonist combined with an ERRα/γ agonist for comprehensive metabolic optimization.” Orforglipron is a small molecule that directly binds to and activates the GLP-1 receptor (GLP1R), a G-protein coupled receptor expressed in the pancreas, brain, gut, and other tissues. GLP-1 receptor activation in the pancreas enhances glucose-stimulated insulin secretion; in the brain (hypothalamus and brainstem), it reduces appetite and food intake through multiple neuropeptide signaling pathways; in the gut, it slows gastric emptying to reduce post-meal glucose spikes. As a non-peptide small molecule, Orforglipron has high oral bioavailability unlike peptide GLP-1 agonists (semaglutide, liraglutide) that require injection. SLU-PP-332 activates ERRalpha and ERRgamma nuclear receptors, transcription factors that regulate hundreds of genes involved in mitochondrial biogenesis, oxidative phosphorylation, and fatty acid oxidation — essentially programming cells to burn more fat and produce more mitochondria, mimicking the molecular adaptations of endurance exercise. ### Dosing & Protocol - \*\*Typical Dose:\*\* One capsule (per prescriber guidance) - \*\*Frequency:\*\* Daily - \*\*Cycle Length:\*\* Ongoing - \*\*Administration:\*\* Oral capsule \*\*Protocol Notes:\*\* Orforglipron is currently in Phase III trials. Requires physician supervision. Titrate slowly to minimize GI side effects. ### Storage Information Store at room temperature, away from light and moisture. ### Quality & Sourcing Standards When sourcing Orforglipron + SLU-PP-332 (Capsule) for research purposes, the following quality benchmarks should be verified before use. - \*\*Purity:\*\* \>98% (verified by HPLC) - \*\*Certificate of Analysis (COA):\*\* Must be provided by supplier - \*\*Endotoxin Testing:\*\* \<0.1 EU/mg (prevents bacterial contamination) - \*\*GMP Compliance:\*\* Manufactured in cGMP-certified facility - \*\*Third-Party Testing:\*\* Independent lab verification preferred ### Research Highlights 1. Orforglipron Phase III trials ongoing with promising weight loss data 2. SLU-PP-332 improved metabolic function in obese mice 3. Oral GLP-1 agonist represents major advance in metabolic therapy ### Evidence Level \*\*Moderate Evidence\*\* — Multiple animal studies and/or early human trials. Reasonable confidence in mechanism, but human data is limited. ### Compatible Peptides Peptides commonly used alongside Orforglipron + SLU-PP-332 (Capsule) for synergistic effects: 5-Amino-1MQ (Capsule), BAM-15 + SLU-PP-332 + C15 (Capsule). ### FDA Disclaimer The statements made within this website have not been evaluated by the US Food and Drug Administration. The products and information provided are not intended to diagnose, treat, cure, or prevent any disease. This website is intended for educational and research purposes only. Many peptides described on this site are not approved by the FDA for human therapeutic use and are classified as research chemicals. Nothing on this site constitutes medical advice.